[Federal Register Volume 85, Number 111 (Tuesday, June 9, 2020)]
[Notices]
[Pages 35314-35315]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-12368]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Development of Medications to Prevent and Treat 
Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trials 
Optional).
    Date: July 9, 2020.
    Time: 10:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neurosciences Center 
Building, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone 
Conference Call).
    Contact Person: Ivan K. Navarro, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, 6001 
Executive Boulevard, Room 4242, MSC 9550, Bethesda, MD 20892 (301) 
827-5833, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; R13 Conference Grant Review.

[[Page 35315]]

    Date: July 10, 2020.
    Time: 1:00 p.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neurosciences Center 
Building, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone 
Conference Call).
    Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, 6001 
Executive Boulevard, Room 4235, MSC 9550, Bethesda, MD 20892-9550 
(301) 827-5819, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Device-Based Treatments for Substance Use Disorders 
(UG3/UH3) (Clinical Trial Optional).
    Date: July 10, 2020.
    Time: 1:00 p.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neurosciences Center 
Building, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone 
Conference Call).
    Contact Person: Ivan K. Navarro, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, 6001 
Executive Boulevard, Room 4242, MSC 9550, Bethesda, MD 20892 (301) 
827-5833, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Implementing the HIV Service Cascade for Justice-
Involved Populations (U01 Clinical Trial Required).
    Date: July 15, 2020.
    Time: 12:00 p.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neurosciences Center 
Building, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone 
Conference Call).
    Contact Person: Sheila Pirooznia, Ph.D., Scientific Review 
Officer, Scientific Review Branch, Division of Extramural Review, 
National Institute on Drug Abuse, 6001 Executive Blvd., Bethesda, MD 
20892 (301) 496-9350, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse and Addiction Research Programs, National 
Institutes of Health, HHS)

    Dated: June 3, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-12368 Filed 6-8-20; 8:45 am]
 BILLING CODE 4140-01-P